Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

AN IMAGEING MARKER FOR PARKINSON'S DISEASE

Award Number: R44NS043826
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2002
PERIOD OF PERFORMANCE END DATE: 05/31/2005

Group Awards By:

View Award Description

AN IMAGEING MARKER FOR PARKINSON'S DISEASE - DESCRIPTION (provided by applicant): The development of disease modifying agents in Parkinson's disease has rapidly expanded the need for in vivo markers for diagnosis and monitoring disease progression. Dopamine transporter (DAT) imaging offers the promise of an objective measure of dopaminergic degeneration allowing for identification of changes in the brain that occur early in the illness, prior to clinical diagnosis. The primary goal of this project is to examine the sensitivity and specificity of DAT imaging using [123I]beta-CIT and SPECT imaging as a diagnostic marker in subjects with suspected PD or PS. We have successfully completed the Phase I pilot study for this project and have utilized these data and experience in designing this Phase II SBIR proposed protocol. The overall study design is to recruit subjects with suspected PD from participating community neurologists and compare the baseline diagnoses of the community neurologists, movement disorders experts and dopamine transporter imaging to a 'gold standard' clinical diagnosis assigned by a movement disorder expert at 12 months follow-up. The DAT imaging diagnosis will be compared to the 'gold standard' clinical diagnosis to determine the sensitivity of [123I]beta-CIT and SPECT imaging as a diagnostic marker in PD and PS. This project is a crucial step to begin to establish [123I]beta-CIT and SPECT imaging as an objective diagnostic biomarker prior to a definitive diagnosis in patients with early parkinsonian symptoms.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2004 ( Subtotal = $380,791 )
2004	2004	MOLECULAR NEUROIMAGING LLC	60 TEMPLE STREET	NEW HAVEN	CT	06510	SOUTH CENTRAL CT	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	7/5/2004	NON-COMPETING CONTINUATION	$380,791
														Subtotal = $380,791

Issue Date FY: 2003 ( Subtotal = $368,864 )
2003	2003	MOLECULAR NEUROIMAGING LLC	60 TEMPLE STREET	NEW HAVEN	CT	06510	SOUTH CENTRAL CT	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2		COMPETING CONTINUATION	$368,864
														Subtotal = $368,864

Grand Total All Awards = $749,655

Top

All Categories

About

Search

Reports

Data Submission

Award Information

AN IMAGEING MARKER FOR PARKINSON'S DISEASE

Award Number: R44NS043826

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2002

PERIOD OF PERFORMANCE END DATE: 05/31/2005

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer